A Phase 3 interventional study of Fluticasone furoate/Vilanterol Inhalation Powder and Fluticasone propionate/salmeterol Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Completed at 63 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 14th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 61 in phase 3, and was the 93rd registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Argentina, Canada and 1 more country
Ages 18+
GlaxoSmithKline · Sites in United States
Ages 12–80
GlaxoSmithKline · Sites in United States, Japan
Ages 12–80
GlaxoSmithKline · Sites in United States
Ages 6–11
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 12+
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
262 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 63 · Phase 2 60 · Phase 3 61 · Phase 4 53
First in 1999; this study’s year is marked. 34 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 810 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 93 across the 238 interventional studies, 512 across the 24 observational. Of the 240 that completed or were terminated, 132 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
5 of the studies in Asthma by GlaxoSmithKline that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
| NCT07712393GlaxoSmithKlineA Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283 | 2027-04-13 |
| NCT06433921GlaxoSmithKlineA Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive | 2027-04-16 |
Add all 5 to your calendar (.ics) → With an account.
Among the 262 studies in Asthma by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily with fluticasone propionate/salmeterol administered twice daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone furoate/vilanterol inhalation powder once daily + placebo inhalation powder twice daily for 24 weeks
Drug: Fluticasone furoate/Vilanterol Inhalation Powder · Drug: Placebo (2)
Fluticasone propionate/salmeterol inhalation powder twice daily + placebo inhalation powder once daily for 24 weeks
Drug: Fluticasone propionate/salmeterol Inhalation Powder · Drug: Placebo (1)
Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
Inhalation powder inhaled orally once daily for 24 weeks
Inhalation powder inhaled orally twice daily for 24 weeks
Change From Baseline in Weighted-mean 24 Hour Serial FEV1 on Day 168/Week 24
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, on Day 168/Week 24. Change from Baseline was calculated as the weighted mean of the 24-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.
Time frame: Baseline and Day 168/Week 24
Serial FEV1 (0-24 Hours)
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . The pre-dose FEV1 assessment and the individual serial FEV1 assessments at Day 168/Week 24 at the indicated time points (pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 11 hours, 12 hours, 12.5 hours, 13 hours, 14 hours, 16 hours, 20 hours, 23 hours, and 24 hour s) were summarized.
Time frame: Day 168
Number of Participants With the Indicated Time to Onset of Bronchodilator Effect at Day 1
Time to onset of bronchodilator effect at Day 1 is defined as the actual time during the 4-hour serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) measurements that the participant first meets or exceeds a 12% and 200 mL increase over Baseline and was derived at Day 1 only. Time to onset was calculated over 0 to 4 hours (5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 4 hours) post-dose. Participants who never exceeded a 12% and 200 mL increase over Baseline were censored at the actual time of their last FEV1 measurement.
Time frame: Baseline to Day 1
Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours Post First Dose (at Randomization)
The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 1 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment.
Time frame: Baseline and Randomization
Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours at Day 168
The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline and Day 168 was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment.
Time frame: Baseline and Day 168
Number of Participants Obtaining a >=12% and >=200 mL Increase From Baseline in FEV1
The number of participants obtaining a \>=12% and \>=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated at 12-hours post-dose and at 24-hours post-dose on Day 168.
Time frame: Baseline and Day 168
Change From Baseline in Trough FEV1 at Day 168
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Trough FEV1 is defined as the pre-dose measurement on Day 168/Week 24. Any missing data at Day 168/Week 24 was imputed using the last observation carried forward (LOCF). Baseline was the pre-dose measurement on Day 1. Change from Baseline was calculated as the pre-dose measurement on Day 168/Week 24 minus the Baseline value.
Time frame: Baseline and Day 168
Baseline FEV1 by Completion Status
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.
Time frame: Baseline
Change From Baseline in Asthma Control Test (ACT) Scores at Day 168
The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, "How much of the time did your asthma keep you from getting as much done at work, school or at home?", "How often have you had shortness of breath?", "How often did your asthma symptoms wake you up at night or earlier than usual in the morning?", "How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?" and "How would you rate your asthma control"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the Day 168 value minus the Baseline value.
Time frame: Baseline and Day 168
Number of Healthcare Contacts Related to Asthma or the Treatment of Asthma From Baseline to Day 168
All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (to the general ward \[GW\] or the intensive care unit \[ICU\]) that were associated with asthma exacerbations were recorded.
Time frame: Baseline to Day 168
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score for Participants 12 Years of Age and Older (AQLQ + 12)
The AQLQ is a disease-specific, self-administered quality of life (QOL) questionnaire developed to evaluate the impact of asthma treatments on the QOL of asthma sufferers. The AQLQ contains 32 items in four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). The response format consists of a 7-point scale: a value of 1 indicates "total impairment"; a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions, provided at least 90% of the questions have been answered; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Change from Baseline was calculated as the Day 168 value minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline total AQLQ score, country, sex, age, and treatment.
Time frame: Baseline and Day 168
Percentage of Participants With "No Problems" in the EQ-5D Descriptive System Dimensions at Day 168/Week 24
The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by a three-point Likert scale (1=no problems, 2=some problems and 3=severe problems). Respondents are asked to choose one level that reflects their "own health state today" for each of the five dimensions.
Time frame: Day 168/Week 24
Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at Day 168
The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). The second part is a 20 centimeter VAS that has endpoints labelled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. Participants were asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS that best represents their own health on that day. Analysis was performed using ANCOVA with covariates of Baseline VAS score, country, sex, age, and treatment.
Time frame: Baseline and Day 168
| Milestone | Fluticasone Propionate 250 µg BID | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|---|
| Started | 1564 | 0 | 0 |
| Completed | 806 | 0 | 0 |
| Not completed | 758 | 0 | 0 |
| Withdrew: Screen failure | 623 | 0 | 0 |
| Withdrew: Run-in failure | 135 | 0 | 0 |
| Milestone | Fluticasone Propionate 250 µg BID | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|---|
| Started | 0 | 403 | 403 |
| Completed | 0 | 358 | 357 |
| Not completed | 0 | 45 | 46 |
| Withdrew: Adverse event | 0 | 6 | 8 |
| Withdrew: Lack of efficacy | 0 | 20 | 11 |
| Withdrew: Protocol violation | 0 | 7 | 10 |
| Withdrew: Lost to follow-up | 0 | 5 | 7 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 7 | 9 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, on Day 168/Week 24. Change from Baseline was calculated as the weighted mean of the 24-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.
| Liters | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| Change From Baseline in Weighted-mean 24 Hour Serial FEV1 on Day 168/Week 24 | 0.341 ± 0.0184 | 0.377 ± 0.0185 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . The pre-dose FEV1 assessment and the individual serial FEV1 assessments at Day 168/Week 24 at the indicated time points (pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 11 hours, 12 hours, 12.5 hours, 13 hours, 14 hours, 16 hours, 20 hours, 23 hours, and 24 hour s) were summarized.
| Liters | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| Pre-dose, n=359,353 | 0.304 ± 0.3575 | 0.323 ± 0.4289 |
| 5 minutes, n=356, 344 | 0.320 ± 0.3573 | 0.339 ± 0.4146 |
| 15 minutes, n=355, 347 | 0.323 ± 0.3565 | 0.354 ± 0.4054 |
| 30 minutes, n=357, 351 | 0.339 ± 0.3614 | 0.366 ± 0.4184 |
| 1 hour, n=358, 353 | 0.344 ± 0.3760 | 0.390 ± 0.4227 |
| 2 hours, n=359, 353 | 0.362 ± 0.3749 | 0.409 ± 0.4204 |
| 3 hours, n=357, 353 | 0.373 ± 0.3764 | 0.419 ± 0.4173 |
| 4 hours, n=357, 354 | 0.356 ± 0.3695 | 0.417 ± 0.4254 |
| 11 hours, n=359, 347 | 0.305 ± 0.3761 | 0.319 ± 0.4099 |
| 12 hours, n=356, 354 | 0.330 ± 0.3691 | 0.338 ± 0.4142 |
| 12.5 hours, n=357, 352 | 0.330 ± 0.3682 | 0.380 ± 0.4117 |
| 13 hours, n=354, 354 | 0.343 ± 0.3602 | 0.396 ± 0.4139 |
| 14 hours, n=356, 353 | 0.357 ± 0.3643 | 0.426 ± 0.4201 |
| 16 hours, n=354, 350 | 0.351 ± 0.3672 | 0.419 ± 0.4152 |
| 20 hours, n=355, 352 | 0.321 ± 0.3757 | 0.376 ± 0.4150 |
| 23 hours, n=354, 353 | 0.310 ± 0.3814 | 0.344 ± 0.4141 |
| 24 hours, n=354, 354 | 0.304 ± 0.3725 | 0.340 ± 0.4032 |
Time to onset of bronchodilator effect at Day 1 is defined as the actual time during the 4-hour serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) measurements that the participant first meets or exceeds a 12% and 200 mL increase over Baseline and was derived at Day 1 only. Time to onset was calculated over 0 to 4 hours (5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 4 hours) post-dose. Participants who never exceeded a 12% and 200 mL increase over Baseline were censored at the actual time of their last FEV1 measurement.
| participants | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| 5 minutes | 100 | 85 |
| 15 minutes | 41 | 51 |
| 30 minutes | 40 | 55 |
| 1 hour | 32 | 39 |
| 2 hours | 19 | 29 |
| 3 hours | 17 | 12 |
| 4 hours | 11 | 12 |
| Censored | 140 | 118 |
The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 1 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment.
| Liters | FFluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours Post First Dose (at Randomization) | 0.316 ± 0.0149 | 0.346 ± 0.0149 |
The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline and Day 168 was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment.
| Liters | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours at Day 168 | 0.360 ± 0.0184 | 0.394 ± 0.0186 |
The number of participants obtaining a \>=12% and \>=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated at 12-hours post-dose and at 24-hours post-dose on Day 168.
| participants | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| 12 hours post-dose, n=356,354 | 199 | 178 |
| 24 hours post-dose, n=354, 354 | 181 | 176 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Trough FEV1 is defined as the pre-dose measurement on Day 168/Week 24. Any missing data at Day 168/Week 24 was imputed using the last observation carried forward (LOCF). Baseline was the pre-dose measurement on Day 1. Change from Baseline was calculated as the pre-dose measurement on Day 168/Week 24 minus the Baseline value.
| Liters | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| Change From Baseline in Trough FEV1 at Day 168 | 0.281 ± 0.0191 | 0.300 ± 0.0193 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.
| Liters | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| All Participants, n=401, 401 | 2.011 ± 0.6389 | 2.048 ± 0.6246 |
| Completers, n=359, 355 | 2.013 ± 0.6530 | 2.043 ± 0.6378 |
| Withdrawals, n=42, 46 | 1.996 ± 0.5081 | 2.091 ± 0.5145 |
The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, "How much of the time did your asthma keep you from getting as much done at work, school or at home?", "How often have you had shortness of breath?", "How often did your asthma symptoms wake you up at night or earlier than usual in the morning?", "How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?" and "How would you rate your asthma control"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the Day 168 value minus the Baseline value.
| Scores on a scale | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| Change From Baseline in Asthma Control Test (ACT) Scores at Day 168 | 2.3 ± 0.16 | 2.0 ± 0.16 |
All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (to the general ward \[GW\] or the intensive care unit \[ICU\]) that were associated with asthma exacerbations were recorded.
| visits per participant | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| Number of Home Visits during the Day | 0.0 ± 0.0 | 0.0 ± 0.05 |
| Number of Home Visits during the Night | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Number of Physician Office/Practice Visits | 0.0 ± 0.29 | 0.0 ± 0.18 |
| Number of Urgent Care/Outpatient Clinic Visits | 0.0 ± 0.05 | 0.0 ± 0.05 |
| Number of Emergency Room Visits | 0.0 ± 0.15 | 0.0 ± 0.14 |
| Number of Inpatient Hospitalization (ICU) Days | 0.0 ± 0.00 | 0.0 ± 0.0 |
| Number of Inpatient Hospitalization (GW) Days | 0.0 ± 0.20 | 0.0 ± 0.39 |
The AQLQ is a disease-specific, self-administered quality of life (QOL) questionnaire developed to evaluate the impact of asthma treatments on the QOL of asthma sufferers. The AQLQ contains 32 items in four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). The response format consists of a 7-point scale: a value of 1 indicates "total impairment"; a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions, provided at least 90% of the questions have been answered; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Change from Baseline was calculated as the Day 168 value minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline total AQLQ score, country, sex, age, and treatment.
| Scores on a scale | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score for Participants 12 Years of Age and Older (AQLQ + 12) | 0.46 ± 0.043 | 0.37 ± 0.043 |
The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by a three-point Likert scale (1=no problems, 2=some problems and 3=severe problems). Respondents are asked to choose one level that reflects their "own health state today" for each of the five dimensions.
| percentage of participants | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| Mobility | 86 | 84 |
| Self care | 98 | 98 |
| Usual activities | 86 | 82 |
| Pain/Discomfort | 70 | 66 |
| Anxiety/Depression | 78 | 81 |
The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). The second part is a 20 centimeter VAS that has endpoints labelled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. Participants were asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS that best represents their own health on that day. Analysis was performed using ANCOVA with covariates of Baseline VAS score, country, sex, age, and treatment.
| scores on a scale | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at Day 168 | 5.5 ± 0.60 | 4.1 ± 0.60 |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of the study medication until Follow-up (up to 544 days).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluticasone Furoate/Vilanterol 100/25 µg OD | — | 4/403 (1%) | 110/403 (27.3%) |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | — | 5/403 (1.2%) | 106/403 (26.3%) |
| Event | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/403 | 2/403 |
| PneumoniaInfections and infestations | 0/403 | 1/403 |
| Upper respiratory tract infectionInfections and infestations | 1/403 | 0/403 |
| Urinary tract infectionInfections and infestations | 0/403 | 1/403 |
| Myocardial ischaemiaCardiac disorders | 1/403 | 0/403 |
| CholelithiasisHepatobiliary disorders | 1/403 | 0/403 |
| Carbon monoxide poisoningInjury, poisoning and procedural complications | 0/403 | 1/403 |
| DisorientationPsychiatric disorders | 0/403 | 1/403 |
| Event | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID |
|---|---|---|
| NasopharyngitisInfections and infestations | 46/403 | 46/403 |
| HeadacheNervous system disorders | 34/403 | 41/403 |
| Upper respiratory tract infectionInfections and infestations | 25/403 | 16/403 |
| CoughRespiratory, thoracic and mediastinal disorders | 15/403 | 13/403 |
| PyrexiaGeneral disorders | 13/403 | 5/403 |
| Age, Continuous(Years) | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID | Total |
|---|---|---|---|
| Mean | 43.8 ± 15.86 | 41.9 ± 16.90 | 42.8 ± 16.41 |
| Gender(Participants) | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID | Total |
|---|---|---|---|
| Female | 244 | 245 | 489 |
| Male | 159 | 158 | 317 |
| Race/Ethnicity, Customized(participants) | Fluticasone Furoate/Vilanterol 100/25 µg OD | Fluticasone Propionate/Salmeterol 250/50 µg BID | Total |
|---|---|---|---|
| African American/African Heritage | 36 | 43 | 79 |
| Asian - Central/South Asian Heritage | 1 | 0 | 1 |
| Asian - East Asian Heritage | 40 | 46 | 86 |
| Asian - Japanese Heritage | 1 | 0 | 1 |
| Asian - South East Asian Heritage | 81 | 79 | 160 |
| Asian - Mixed Race | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| White - Arabic/North African Heritage | 1 | 0 | 1 |
| White - White/Caucasian/European Heritage | 241 | 232 | 473 |
| Mixed Race | 0 | 2 | 2 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jun 2010, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 2 years 2 months after primary completion. A results delay was requested in Mar 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.